Last €34.83 EUR
Change Today +0.265 / 0.77%
Volume 866.0
NZM2 On Other Exchanges
As of 10:07 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

novozymes a/s-b shares (NZM2) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/14 - €37.97
52 Week Low
10/15/13 - €26.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVOZYMES A/S-B SHARES (NZM2)

Related News

No related news articles were found.

novozymes a/s-b shares (NZM2) Related Businessweek News

No Related Businessweek News Found

novozymes a/s-b shares (NZM2) Details

Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. The company offers solutions for the agriculture industry, including enzymes to enhance digestibility and nutritional value of animal feed; microbial solutions to maintain water quality, limit risks of disease, and enhance yields in aquaculture; and microbial-based biofertility, biocontrol, and bioyield enhancer products to naturally produce healthier crops and enhance yields. It also provides a portfolio of enzymes for application in biofuel production; recombinant products and technologies to the medical device and drug delivery market; and food and beverages enzymes for applications in baking, brewing, dairy, distilling, flavor enhancement, food specialties, health and nutrition, juice, meat processing, oils and fats, starch, and wine industries. In addition, the company offers household care enzyme and microbial agents for use in cleaning solutions, dishwashing, and laundry; enzymes for biopreparation, degreasing, and re-bating of leather; enzymes for pulp and paper production processes, such as bleach boosting, deinking, drainage enhancement, effluent control, pitch control, refining, slime control, starch modification, and stickies control; enzymatic solutions for processing textiles; and microbial solutions for biological wastewater treatment. Novozymes A/S has a strategic alliance with Monsanto Company to discover, develop, and sell microbial solutions for farmers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

6,205 Employees
Last Reported Date: 08/14/14
Founded in 1925

novozymes a/s-b shares (NZM2) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr8.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Executive Vice President of Supply Operations
Total Annual Compensation: kr5.2M
CSO and Executive Vice President of Research ...
Total Annual Compensation: kr5.0M
Executive Vice President of Business Operatio...
Total Annual Compensation: kr3.6M
Compensation as of Fiscal Year 2013.

novozymes a/s-b shares (NZM2) Key Developments

Novozymes A/S Reports Unaudited Group Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Year 2014

Novozymes A/S reported unaudited group earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of DKK 3,061 million compared to DKK 3,025 million a year ago. EBITDA was DKK 1,011 million compared to DKK 926 million a year ago. EBIT (operating profit) was DKK 787 million compared to DKK 734 million a year ago. Profit before tax was DKK 767 million compared to DKK 680 million a year ago. Net profit attributable to Shareholders in the company was DKK 591 million compared to DKK 555 million a year ago. Diluted earnings per share were DKK 1.87 against DKK 1.75 a year ago. The company reported net profit growth was strong in the second quarter, driven by a one-off deferred tax effect following the enactment of a new lower corporate tax rate in Denmark. For the six months, the company reported revenue of DKK 6,094 million compared to DKK 5,870 million a year ago. Exchange rates had a negative impact on sales, and sales in LCY were up by 8%. Acquisitions and The BioAg Alliance had a minor impact on sales growth and, organically, sales grew by 8%. Sales to the Bioenergy industry were the significant contributor to sales growth. EBITDA was DKK 2,178 million compared to DKK 1,810 million a year ago. EBIT (operating profit) was DKK 1,710 million compared to DKK 1,443 million a year ago. Profit before tax was DKK 1,669 million compared to DKK 1,341 million a year ago. Net profit attributable to Shareholders in the parent company was DKK 1,284 million compared to DKK 1,069 million a year ago. Diluted earnings per share were DKK 4.05 against DKK 3.37 a year ago. Cash flow from operating activities was DKK 3,204 million compared to DKK 1,012 million a year ago. Purchase of property, plant and equipment was DKK 206 million against DKK 342 million a year ago. Return on equity was 23.5% compared to 21.8% a year ago. Net interest-bearing debt as on June 30, 2014 was negative DKK 961 million compared to positive DKK 1,888 million as of June 30, 2013. The full-year of 2014 sales growth outlook is maintained. Full-year expectations for EBIT and net profit growth are increased to 9-11%, up from 8%-10%. Expectations for ROIC, including goodwill, are adjusted to negative 22%, up from 21-22%. Expectation for free cash flow are increased by DKK 500 million, coming from, in rough numbers, DKK 200 million from lower CapEx, DKK 100 million from changing in cash management practice in China and around DKK 150 million more in cash impact from the BioAg Alliance. That brings to DKK 3.8 billion to DKK 3.9 billion free cash flow for the full year. The effective tax rate is still expected at 23%.

Novozymes A/S Presents at Handelsbanken Nordic Large Cap Seminar, Sep-08-2014

Novozymes A/S Presents at Handelsbanken Nordic Large Cap Seminar, Sep-08-2014 . Venue: Stockholm, Sweden.

Novozymes A/S Presents at Kempen Resource Efficiency & Cleantech, Sep-11-2014

Novozymes A/S Presents at Kempen Resource Efficiency & Cleantech, Sep-11-2014 . Venue: Savoy Hotel, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NZM2:GR €34.83 EUR +0.265

NZM2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aryzta AG SFr.81.85 CHF +0.15
Chr Hansen Holding A/S kr225.20 DKK +2.60
Ebro Foods SA €15.39 EUR +0.34
EMS-Chemie Holding AG SFr.411.50 CHF -1.00
Kerry Group PLC €55.00 EUR -0.52
View Industry Companies

Industry Analysis


Industry Average

Valuation NZM2 Industry Range
Price/Earnings 32.2x
Price/Sales 6.4x
Price/Book 7.1x
Price/Cash Flow 27.0x
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOZYMES A/S-B SHARES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at